Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.

Christophe ChaignotMahmoud ZureikGrégoire ReyRosemary Dray-SpiraJoël CosteAlain Weill

Published in: Pharmacoepidemiology and drug safety (2018)

This study raises concerns about the safety of baclofen for AUD, particularly at high doses, with higher risks of hospitalisation and mortality than approved drugs.

Keyphrases

cardiovascular events
alcohol use disorder
risk factors
cardiovascular disease
human health
coronary artery disease
risk assessment